Skip to main content
NIH funding notice PA-18-753

Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R01 Clinical Trial Optional)

Closed on May 7, 2021.

Posted
April 11, 2018
Close date
May 7, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,417,158 in first-year total cost, median $708,579.

Most frequent study sections

  1. Population and Public Health Approaches to HIV/AIDS Study Section[PPAH]1
  2. Special Emphasis Panel[ZRG1 IDIB-M (02)]1

Most frequent institutions

  1. TRIAD NATIONAL SECURITY, LLC1
  2. UNIVERSITY OF SOUTHERN CALIFORNIA1
Competing awards under PA-18-753 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2021HIV Incidence and Drug Resistance Surveillance using Microdrop HIV Sequencing2R01AI095066-11A1LEE, HA YOUNUNIVERSITY OF SOUTHERN CALIFORNIA, CA$712,130ZRG1
2021Next-generation algorithms using multiple biomarkers for precise estimation of HIV infection duration and population level incidence1R01AI152897-01A1LEITNER, THOMAS K.TRIAD NATIONAL SECURITY, LLC, NM$705,028PPAH

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PA-18-753: Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R01 Clinical Trial Optional) | ScienceDex | ConductScience